no site and no over all conatct

Clinical Trial for New Migraine Treatment

Recruiting
100 years or below
Male
Fase N/A
1 Location

Brief description of study

no site and no over all conatct

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: PKU, Phenylketonuria, gene therapy
  • Age: 100 years or below
  • Gender: Male

Inclusion Criteria:
Exclusion Criteria:

Updated on 19 Feb 2024. Study ID: TX13221

This clinical trial aims to evaluate the effectiveness of a new medication for treating migraines. Participants will be randomly assigned to receive either the new medication or a placebo, which is a substance with no active therapeutic effect. The study seeks to determine if the new treatment can reduce the frequency and severity of migraine attacks compared to the placebo.

  • Who Can Participate: Adults aged 18-65 who have been diagnosed with migraines and experience at least four migraine days per month
  • Study Details: Participants will be randomly assigned to receive either the new medication or a placebo. The study will assess the medication's impact on the frequency and severity of migraines
  • Study Timelines and Visits: The study will last 6 months.The study requires 5 visits

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language